CD38 is a 42 kD type II transmembrane glycoprotein that uses nicotinamide adenine dinucleotide (NAD) as a substrate to form cyclic adenosine diphosphate ribose (cADPR). This novel multifunctional ectoenzyme has both cyclase and hydrolase enzymatic activity, and is expressed on the surface of most white blood cells (CD4+, CD8+, B-lymphocytes and natural killer (NK) cells). It is also expressed at high levels in normal tissues and organs like the pancreas, liver, and kidney as well as in malignant lymphoma and neuroblastoma. In addition to having a key role in lymphocyte activation and differentiation, CD38 is also involved in cell adhesion, signal transduction, insulin secretion, and calcium signaling.
-Immunohistochemistry-Paraffin-NBP2-25250-img0004.jpg)
Immunohistochemistry-Paraffin: CD38 Antibody
A very recent review by Chilemi et al examines the role of CD38 in shaping the bone marrow microenvironment by incorporating both old and new models1. This review focuses specifically on myeloma and chronic lymphocytic leukemia (CLL) and suggests that CD38 status may strongly impact and guide antibody-mediate immunotherapy. Wei’s group details the CD38 signaling pathway in a recent paper that summarizes the pathway modules and highlights recent advances with respect to Ca2+ mobilization2. Use of CD38 as an independent negative prognostic marker for CLL is detailed in a review by Vaisitti’s group3. They share the evolution of CD38 from a marker to a disease modifier to a potential therapeutic marker. Novus Biologicals offers CD38 reagents for your research needs including:
PMIDs
